Mangold Fondkommission AB published an Analyst Report on 2cureX

May 6 | 2021

Copenhagen — May 6, 2021 — Mangold Fondkommission AB issued today an Equity Analyst Report on 2cureX (Insight.Mangold (https://insight.mangold.se/wp-content/uploads/2021/05/2cureX_initialanalysis_english_2021-05-06.pdf)).

The report is available in both Swedish and English at 2cureX’s web-site (Analyst Coverage).

For more information:

Fernando Andreu, Chief Executive Officer
E-mail: fa@2curex.com
Telephone: +45 2279 5399
www.2curex.com

Certified Adviser

Redeye AB

Phone: +46 8 121 576 90

Mail: certifiedadviser@redeye.se

—

About 2cureX

2cureX has developed the IndiTreat® (Individual Treatment) test. IndiTreat® establishes thousands of 3D microtumors that functionally resemble the patient's tumor and identifies the approved cancer treatment that most effectively kills the patient's tumor. Immediately after the test, the patient is given the selected treatment.

The first IndiTreat® product in metastatic colorectal cancer is introduced to the European market. Subsequent products help patients at different stages of colorectal cancer and other solid cancers.

The company is listed on Nasdaq First North Growth Market in Stockholm (symbol: "2CUREX"). For more information about 2cureX visit www.2cureX.com.